Cited by 780HER2/EGFR in Cancer ResearchLung Cancer Treatments and MutationsCancer Genomics and Diagnostics

The DOI matches its Crossref record; 53 of the 54 references it cites were found in a registry or an index.

HER kinase inhibition in patients with HER2- and HER3-mutant cancers

Open access

Hyman, David M., Piha-Paul, Sarina A., Won, Helen, Rodon, Jordi, Saura, Cristina, Shapiro, Geoffrey I., Juric, Dejan, Quinn, David I., Moreno, Victor, Doger, Bernard, Mayer, Ingrid A., Boni, Valentina, Calvo, Emiliano, Loi, Sherene, Lockhart, Albert C., Erinjeri, Joseph P., Scaltriti, Maurizio, Ulaner, Gary A., Patel, Juber, Tang, Jiabin, Beer, Hannah, Selcuklu, S. Duygu, Hanrahan, Aphrothiti J., Bouvier, Nancy, Melcer, Myra, Murali, Rajmohan, Schram, Alison M., Smyth, Lillian M., Jhaveri, Komal, Li, Bob T., Drilon, Alexander, Harding, James J., Iyer, Gopa, Taylor, Barry S., Berger, Michael F., Cutler Jr, Richard E., Xu, Feng, Butturini, Anna, Eli, Lisa D., Mann, Grace, Farrell, Cynthia, Lalani, Alshad S., Bryce, Richard P., Arteaga, Carlos L., Meric-Bernstam, Funda, Baselga, José, Solit, David B.·2018·Nature

DOI 10.1038/nature25475PMC PMC5808581

Open this paper in CoChat — free account

Abstract

Somatic mutations of ERBB2 and ERBB3 (which encode HER2 and HER3, respectively) are found in a wide range of cancers. Preclinical modelling suggests that a subset of these mutations lead to constitutive HER2 activation, but most remain biologically uncharacterized. Here we define the biological and therapeutic importance of known oncogenic HER2 and HER3 mutations and variants of unknown biological importance by conducting a multi-histology, genomically selected, 'basket' trial using the pan-HER kinase inhibitor neratinib (SUMMIT; clinicaltrials.gov identifier NCT01953926). Efficacy in HER2-mutant cancers varied as a function of both tumour type and mutant allele to a degree not predicted by preclinical models, with the greatest activity seen in breast, cervical and biliary cancers and with tumours that contain kinase domain missense mutations. This study demonstrates how a molecularly driven clinical trial can be used to refine our biological understanding of both characterized and new genomic alterations with potential broad applicability for advancing the paradigm of genome-driven oncology.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1038/nature25475

Cites

53 of 53 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

KEGG: Kyoto Encyclopedia of Genes and Genomes
Kanehisa, M. (2000) · Nucleic Acids Research · doi:10.1093/nar/28.1.27 · Cited by 37,077
KEGG: Kyoto Encyclopedia of Genes and Genomes
Ogata, H., Goto, S., Sato, K., Fujibuchi, W., Bono, H., & Kanehisa, M. (1999) · Nucleic Acids Research · doi:10.1093/nar/27.1.29 · Cited by 31,232
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay‐Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,320
Self-citation
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2
Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103153441101 · Cited by 11,500
Self-citation
Signatures of mutational processes in human cancer
Initiative, A. P. C. G., Alexandrov, L. B., ICGC Breast Cancer Consortium, ICGC MMML-Seq Consortium, PedBrain, I., Nik-Zainal, S., Wedge, D. C., Aparicio, S. A. J. R., Behjati, S., Biankin, A. V., et al. (2013) · Nature · doi:10.1038/nature12477 · Cited by 9,660
Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer
Borghaei, H., Paz-Ares, L., Horn, L., Spigel, D. R., Steins, M., Ready, N. E., Chow, L. Q., Vokes, E. E., Felip, E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1507643 · Cited by 9,335
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
Bang, Y.-J., Van Cutsem, E., Feyereislova, A., Chung, H. C., Shen, L., Sawaki, A., Lordick, F., Ohtsu, A., Omuro, Y., Satoh, T., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)61121-x · Cited by 7,302
Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
Le, D. T., Durham, J. N., Smith, K. N., Wang, H., Bartlett, B. R., Aulakh, L. K., Lu, S., Kemberling, H., Wilt, C., Luber, B. S., et al. (2017) · Science · doi:10.1126/science.aan6733 · Cited by 6,645
Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update
Wolff, A. C., Hammond, M. E. H., Hicks, D. G., Dowsett, M., McShane, L. M., Allison, K. H., Allred, D. C., Bartlett, J. M. S., Bilous, M., Fitzgibbons, P. L., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.50.9984 · Cited by 4,080
From RECIST to PERCIST: Evolving Considerations for PET Response Criteria in Solid Tumors
Wahl, R. L., Jacene, H., Kasamon, Y., & Lodge, M. A. (2009) · Journal of Nuclear Medicine · doi:10.2967/jnumed.108.057307 · Cited by 3,777

Flagged first, then by citations

Show all 54 references

1 of the 54 references couldn’t be matched to a known paper.

Sorted by citations

Items 101–200 of 779

Antitumour activity of neratinib in patients with HER2-mutant advanced biliary tract cancers
Harding, J. J., Piha-Paul, S. A., Shah, R. H., Murphy, J., Cleary, J. M., Shapiro, G. I., Quinn, D. I., Braña, I., Moreno, V., Borad, M. J., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-36399-y · Cited by 98
Self-citation
Genomic profile of advanced breast cancer in circulating tumour DNA
Kingston, B., Cutts, R. J., Bye, H., Beaney, M., Walsh-Crestani, G., Hrebien, S., Swift, C., Kilburn, L., Kernaghan, S., Moretti, L., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-22605-2 · Cited by 98
Therapeutic options for mucinous ovarian carcinoma
Gorringe, K. L., Cheasley, D. A., Wakefield, M. J., Ryland, G. L., Allan, P. E., Alsop, K., Amarasinghe, K. C., Ananda, S. S., Bowtell, D. D. L., Christie, M., et al. (2020) · Gynecologic Oncology · doi:10.1016/j.ygyno.2019.12.015 · Cited by 93
The evolving panorama of HER2-targeted treatments in metastatic urothelial cancer: A systematic review and future perspectives
Patelli, G., Zeppellini, A., Spina, F., Righetti, E., Stabile, S., Amatu, A., Tosi, F., Ghezzi, S., Siena, S., & Bianchi, A. S. (2022) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2022.102351 · Cited by 93
The Emerging Potential for Network Analysis to Inform Precision Cancer Medicine
Öztürk, K., Dow, M. T., Carlin, D. E., Bejar, R. L., & Carter, H. K. (2018) · Journal of Molecular Biology · doi:10.1016/j.jmb.2018.06.016 · Cited by 90
Prevalence and role of HER2 mutations in cancer
Cocco, E., Lopez, S., Santin, A. D., & Scaltriti, M. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.03.010 · Cited by 89
Self-citation
Dynamic Cancer Cell Heterogeneity: Diagnostic and Therapeutic Implications
Jacquemin, V., Antoine, M., Dom, G., Detours, V., Maenhaut, C., & Dumont, J. E. (2022) · Cancers · doi:10.3390/cancers14020280 · Cited by 92
Activity of Afatinib in Heavily Pretreated Patients With ERBB2 Mutation–Positive Advanced NSCLC: Findings From a Global Named Patient Use Program
Peters, S., Fontecedro, A. C., Nechushtan, H., Shih, J., Liao, W., Gautschi, O. P., Spataro, V. J., Unk, M., Yang, J. C., Lorence, R. M., et al. (2018) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2018.07.093 · Cited by 85
The force of HER2 – A druggable target in NSCLC?
Jebbink, M., Langen, A. J. D., Boelens, M. C., Monkhorst, K., & Smit, E. F. (2020) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2020.101996 · Cited by 85
Twenty Years with Personalized Medicine: Past, Present, and Future of Individualized Pharmacotherapy
Jørgensen, J. T. (2019) · The Oncologist · doi:10.1634/theoncologist.2019-0054 · Cited by 81
Somatic Mutations in HER2 and Implications for Current Treatment Paradigms in HER2-Positive Breast Cancer
Gaibar, M., Beltrán, L., Romero‐Lorca, A., Fernández‐Santander, A., & Novillo, A. (2020) · Journal of Oncology · doi:10.1155/2020/6375956 · Cited by 81
Histology-agnostic drug development — considering issues beyond the tissue
Pestana, R. C., Sen, S., Hobbs, B. P., & Hong, D. S. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-0384-0 · Cited by 82
Predicting gene mutation status via artificial intelligence technologies based on multimodal integration (MMI) to advance precision oncology
Shao, J., Ma, J., Zhang, Q., Li, W., & Wang, C. (2023) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2023.02.006 · Cited by 85
Targeted and novel therapy in advanced gastric cancer
Selim, J. H., Shaheen, S., Sheu, W.-C., & Hsueh, C.-T. (2019) · Experimental Hematology and Oncology · doi:10.1186/s40164-019-0149-6 · Cited by 81
Second-line Treatment in Advanced Biliary Tract Cancer: Today and Tomorrow
Rizzo, A., Ricci, A. D., Tober, N., Nigro, M. C., Mosca, M., Palloni, A., Abbati, F., Frega, G., Lorenzo, S. D., Tavolari, S., et al. (2020) · Anticancer Research · doi:10.21873/anticanres.14282 · Cited by 80
Integrated Analysis of RNA and DNA from the Phase III Trial CALGB 40601 Identifies Predictors of Response to Trastuzumab-Based Neoadjuvant Chemotherapy in HER2-Positive Breast Cancer
Tanioka, M., Fan, C., Parker, J. S., Hoadley, K. A., Hu, Z., Yan, L., Hyslop, T., Pitcher, B. N., Soloway, M. G., Spears, P. A., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-3431 · Cited by 79
Trastuzumab resistance in HER2-positive breast cancer: Mechanisms, emerging biomarkers and targeting agents
Wang, Z.-H., Zheng, Z.-Q., Jia, S., Liu, S.-N., Xiao, X.-F., Chen, G., Liang, W., & Lu, X.-F. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.1006429 · Cited by 79
Afatinib in patients with metastatic or recurrent HER2-mutant lung cancers: a retrospective international multicentre study
Lai, W. V., Lebas, L., Barnes, T. A., Milia, J., Ni, A., Gautschi, O. P., Peters, S., Ferrara, R., Plodkowski, A. J., Kavanagh, J., et al. (2019) · European Journal of Cancer · doi:10.1016/j.ejca.2018.11.030 · Cited by 79
Self-citation
Rational development of combination therapies for biliary tract cancers
Harding, J. J., Khalil, D. N., Fabris, L., & Abou‐Alfa, G. K. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2022.09.004 · Cited by 80
Self-citation
MyPathway Human Epidermal Growth Factor Receptor 2 Basket Study: Pertuzumab + Trastuzumab Treatment of a Tissue-Agnostic Cohort of Patients With Human Epidermal Growth Factor Receptor 2–Altered Advanced Solid Tumors
Sweeney, C. J., Hainsworth, J. D., Bose, R., Burris, H. A., Kurzrock, R., Swanton, C., Friedman, C. F., Spigel, D. R., Szado, T., Schulze, K., et al. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.22.02636 · Cited by 78
Self-citation
Zongertinib (BI 1810631), an Irreversible HER2 TKI, Spares EGFR Signaling and Improves Therapeutic Response in Preclinical Models and Patients with HER2-Driven Cancers
Wilding, B., Woelflingseder, L., Baum, A., Chylinski, K., Vainorius, G., Gibson, N. J., Waizenegger, I. C., Gerlach, D., Augsten, M., Spreitzer, F., et al. (2024) · Cancer Discovery · doi:10.1158/2159-8290.cd-24-0306 · Cited by 78
High-Throughput Functional Evaluation of Variants of Unknown Significance in ERBB2
Nagano, M., Kohsaka, S., Ueno, T., Kojima, S., Saka, K., Iwase, H., Kawazu, M., & Mano, H. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-0991 · Cited by 79
Biomarkers for HER2-positive metastatic breast cancer: Beyond hormone receptors
Dieci, M. V., Miglietta, F., Griguolo, G., & Guarneri, V. (2020) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2020.102064 · Cited by 74
Limited evolution of the actionable metastatic cancer genome under therapeutic pressure
van de Haar, J., Hoes, L. R., Roepman, P., Lolkema, M. P., Verheul, H. M. W., Gelderblom, H. A. J., Langen, A. J. D., Smit, E. F., Cuppen, E. P. J. G., Wessels, L. F. A., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01448-w · Cited by 74
Neratinib + fulvestrant + trastuzumab for HR-positive, HER2-negative, HER2-mutant metastatic breast cancer: outcomes and biomarker analysis from the SUMMIT trial
Jhaveri, K. L., Eli, L. D., Wildiers, H. P. M. W., Hurvitz, S. A., Zotano, Á. G., Unni, N. G., Brufsky, A., Park, H., Waisman, J. R., Yang, E. S.-H., et al. (2023) · Annals of Oncology · doi:10.1016/j.annonc.2023.08.003 · Cited by 74
Self-citation
Neratinib is effective in breast tumors bearing both amplification and mutation of ERBB2 (HER2)
Cocco, E., Carmona, F. J., Razavi, P., Won, H. H., Cai, Y., Rossi, V., Chan, C., Cownie, J., Soong, J., Toska, E., et al. (2018) · Science Signaling · doi:10.1126/scisignal.aat9773 · Cited by 74
Self-citation
Neratinib in patients with HER2-mutant, metastatic cervical cancer: Findings from the phase 2 SUMMIT basket trial
Oaknin, A., Friedman, C. F., Roman, L. D., D'souza, A., Braña, I., Bidard, F., Goldman, J. W., Alvarez, E. A., Boni, V., ElNaggar, A. C., et al. (2020) · Gynecologic Oncology · doi:10.1016/j.ygyno.2020.07.025 · Cited by 73
Self-citation
Biliary Tract Cancer: Current Medical Treatment Strategies
Oneda, E., Hilal, M. A., & Zaniboni, A. (2020) · Cancers · doi:10.3390/cancers12051237 · Cited by 73
Microsatellite Instability–High Endometrial Cancers with MLH1 Promoter Hypermethylation Have Distinct Molecular and Clinical Profiles
Manning‐Geist, B. L., Liu, Y. L., Devereaux, K. A., Paula, A. D. C., Zhou, Q. C., Ma, W., Selenica, P., Ceyhan‐Birsoy, O., Moukarzel, L. A., Hoang, T. J., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-0713 · Cited by 75
Multicenter phase II trial of trastuzumab deruxtecan for HER2-positive unresectable or recurrent biliary tract cancer: HERB trial
Ohba, A., Morizane, C., Ueno, M., Kobayashi, S., Kawamoto, Y., Komatsu, Y., Ikeda, M., Sasaki, M., Okano, N., Furuse, J., et al. (2022) · Future Oncology · doi:10.2217/fon-2022-0214 · Cited by 73
Targeting HER2 alterations in non-small cell lung cancer: Therapeutic breakthrough and challenges
Yu, Y., Yang, Y., Li, H., & Fan, Y. (2023) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2023.102520 · Cited by 75
Progress in systemic therapy for advanced-stage urothelial carcinoma
Nadal, R., Valderrama, B. P., & Joaquim Bellmunt, B. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00826-2 · Cited by 76
New directions in clinical trials for frontotemporal lobar degeneration: methods and outcome measures
Boxer, A. L., Gold, M., Feldman, H., Boeve, B. F., Dickinson, S. L.-J., Fillit, H., Ho, C., Paul, R., Pearlman, R., Sutherland, M., et al. (2020) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2019.06.4956 · Cited by 71
Sevabertinib in Advanced HER2 -Mutant Non–Small-Cell Lung Cancer
Le, X., Kim, T. M., Loong, H. H., Prelaj, A., Goh, B. C., Li, L., Fang, Y., Lu, S., Dong, X., Wu, L., et al. (2025) · New England Journal of Medicine · doi:10.1056/nejmoa2511065 · Cited by 70
Activity of a novel HER2 inhibitor, poziotinib, for HER2 exon 20 mutations in lung cancer and mechanism of acquired resistance: An in vitro study
Koga, T., Kobayashi, Y., Tomizawa, K., Suda, K., Kosaka, T., Sesumi, Y., Fujino, T., Nishino, M., Ohara, S., Chiba, M., et al. (2018) · Lung Cancer · doi:10.1016/j.lungcan.2018.10.019 · Cited by 70
Genomics and Targeted Therapies in Gastroesophageal Adenocarcinoma
Nagaraja, A. K., Kikuchi, O., & Bass, A. J. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-0487 · Cited by 70
Molecular landscape and efficacy of HER2-targeted therapy in patients with HER2-mutated metastatic breast cancer
Yi, Z., Rong, G., Guan, Y., Li, J., Chang, L., Li, H., Liu, B., Wang, W., Guan, X., Ouyang, Q., et al. (2020) · npj Breast Cancer · doi:10.1038/s41523-020-00201-9 · Cited by 70
Massively parallel sequencing analysis of 68 gastric-type cervical adenocarcinomas reveals mutations in cell cycle-related genes and potentially targetable mutations
Selenica, P., Alemar, B., Matrai, C. E., Talia, K. L., Veras, E. F. T., Hussein, Y. R., Oliva, E., Beets‐Tan, R. G. H., Mikami, Y., McCluggage, W. G., et al. (2020) · Modern Pathology · doi:10.1038/s41379-020-00726-1 · Cited by 71
Self-citation
Comparative analysis of drug response and gene profiling of HER2-targeted tyrosine kinase inhibitors
Conlon, N. T., Kooijman, J. J., van Gerwen, S. J. C., Mulder, W. R., Zaman, G. J. R., Diala, I., Eli, L. D., Lalani, A. S., Crown, J. P., & Collins, D. M. (2021) · British Journal of Cancer · doi:10.1038/s41416-020-01257-x · Cited by 71
Self-citation
Landscape of circulating tumour DNA in metastatic breast cancer
Davis, A. A., Jacob, S. L., Gerratana, L., Shah, A. N., Wehbe, F., Katam, N., Zhang, Q., Flaum, L., Siziopikou, K. P., Platanias, L. C., et al. (2020) · EBioMedicine · doi:10.1016/j.ebiom.2020.102914 · Cited by 69
Anti-HER2 therapy in metastatic breast cancer: many choices and future directions
Wynn, C., & Tang, S. (2022) · Cancer and Metastasis Reviews · doi:10.1007/s10555-022-10021-x · Cited by 75
Molecular Landscape of ERBB2/ERBB3 Mutated Colorectal Cancer
Loree, J. M., Bailey, A. M., Johnson, A. M., Yu, Y., Wu, W., Bristow, C. A., Davis, J. S., Shaw, K. R., Broaddus, R., Banks, K. C., et al. (2018) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djy067 · Cited by 68
Self-citation
Personalized biomarker-based treatment strategy for patients with squamous cell carcinoma of the head and neck: EORTC position and approach
Galot, R., Tourneau, C. L., Guigay, J., Licitra, L. F., Tinhofer, I., Kong, A. H., Caballero, C. A., Fortpied, C., Bogaerts, J., Govaerts, A.-S., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy452 · Cited by 67
Progress and challenges in HER2-positive gastroesophageal adenocarcinoma
Zhao, D., Klempner, S. J., & Chao, J. (2019) · Journal of Hematology & Oncology · doi:10.1186/s13045-019-0737-2 · Cited by 66
HER family in cancer progression: From discovery to 2020 and beyond
Kumar, R., George, B., Campbell, M. R., Verma, N., Paul, A. M., Melo-Alvim, C., Ribeiro, L., Pillai, M. R., Costa, L., & Moasser, M. M. (2020) · Advances in cancer research · doi:10.1016/bs.acr.2020.04.001 · Cited by 66
Beyond HER2: Targeting the ErbB receptor family in breast cancer
Drago, J. Z., Ferraro, E., Abuhadra, N. K., & Modi, S. (2022) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2022.102436 · Cited by 65
Molecular Testing in Breast Cancer
Litton, J. K., Burstein, H. J., & Turner, N. C. (2019) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_237715 · Cited by 67
Trastuzumab rezetecan, a HER2-directed antibody–drug conjugate, in patients with advanced HER2-mutant non-small-cell lung cancer (HORIZON-Lung): phase 2 results from a multicentre, single-arm study
Li, Z., Wang, Y., Sun, Y., Wang, L., Li, X., Sun, L., He, Z., Yang, H., Wang, Y., Wang, Q., et al. (2025) · The Lancet Oncology · doi:10.1016/s1470-2045(25)00012-9 · Cited by 64
Molecular Pathways and Mechanisms of HER2 in Cancer Therapy
Raghav, K. P. S., & Moasser, M. M. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-0283 · Cited by 65
Mutation Variants and Co-Mutations as Genomic Modifiers of Response to Afatinib in HER2-Mutant Lung Adenocarcinoma
Fang, W., Zhao, S., Liang, Y., Yang, Y., Yang, L., Dong, X., Zhang, L., Shoufeng, W., Yang, Y., Yang, Y., et al. (2019) · The Oncologist · doi:10.1634/theoncologist.2019-0547 · Cited by 63
Combining Neratinib with CDK4/6, mTOR, and MEK Inhibitors in Models of HER2-positive Cancer
Zhao, M., Scott, S. M., Evans, K. W., Yuca, E., Saridogan, T., Zheng, X., Wang, H., Korkut, A., Pico, C. X. C., Demirhan, M. E., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-3017 · Cited by 62
Self-citation
Poziotinib in Treatment-Naive NSCLC Harboring HER2 Exon 20 Mutations: ZENITH20-4, A Multicenter, Multicohort, Open-Label, Phase 2 Trial (Cohort 4)
Cornelissen, R., Prelaj, A., Sun, S. B., Baik, C. S., Wollner, M., Haura, E. B., Mamdani, H. M., Riess, J. W., Cappuzzo, F., Garassino, M. C., et al. (2023) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2023.03.016 · Cited by 62
New Targets in Lung Cancer (Excluding EGFR, ALK, ROS1)
Russo, A., Lopes, A. R., McCusker, M. G., Garrigues, S. G., Ricciardi, G. R. R., Arensmeyer, K. E., Scilla, K. A., Mehra, R., & Rolfo, C. D. (2020) · Current Oncology Reports · doi:10.1007/s11912-020-00909-8 · Cited by 65
Mutational landscape and characteristics of ERBB2 in non‐small cell lung cancer
Wei, X., Gao, X., Zhang, X., Yang, J., Chen, Z., Wu, Y.-L. L. C., & Zhou, Q. H. (2020) · Thoracic Cancer · doi:10.1111/1759-7714.13419 · Cited by 62
The Phase II MutHER Study of Neratinib Alone and in Combination with Fulvestrant in HER2-Mutated, Non-amplified Metastatic Breast Cancer
Ma, C. X., Luo, J., Freedman, R. A., Pluard, T. J., Nangia, J. R., Lu, J., Valdez-Albini, F., Cobleigh, M., Jones, J. M., Lin, N., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-3418 · Cited by 59
Self-citation
Basket Trials: Review of Current Practice and Innovations for Future Trials
Hobbs, B. P., Pestana, R. C., Zabor, E. C., Kaizer, A. M., & Hong, D. S. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.21.02285 · Cited by 64
Neratinib for HER2-positive breast cancer with an overlooked option
Guo, L., Shao, W., Zhou, C., Yang, H. J., Yang, L., Cai, Q., Wang, J., Shi, Y., Huang, L., & Zhang, J. (2023) · Molecular Medicine · doi:10.1186/s10020-023-00736-0 · Cited by 59
Molecular landscape of ERBB2 alterations in 3000 advanced NSCLC patients
Hong, L., Patel, S. A., Drusbosky, L. M., Xiong, Y., Chen, R., Geng, R., Heeke, S., Nilsson, M. B., Wu, J., Heymach, J. V., et al. (2024) · npj Precision Oncology · doi:10.1038/s41698-024-00720-9 · Cited by 62
Transitioning the Molecular Tumor Board from Proof of Concept to Clinical Routine: A German Single-Center Analysis
Hoefflin, R., Lazarou, A., Hess, M. E., Reiser, M., Wehrle, J., Metzger, P., Frey, A. V., Becker, H., Aumann, K., Berner, K., et al. (2021) · Cancers · doi:10.3390/cancers13051151 · Cited by 59
Modeling biological and genetic diversity in upper tract urothelial carcinoma with patient derived xenografts
Kim, K., Hu, W., Audenet, F., Almassi, N., Hanrahan, A. J., Murray, K. S., Bagrodia, A., Wong, N. C., Clinton, T. N., Dason, S., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-15885-7 · Cited by 59
Self-citation
Targeting HER2 Exon 20 Insertion–Mutant Lung Adenocarcinoma with a Novel Tyrosine Kinase Inhibitor Mobocertinib
Han, H., Li, S., Chen, T., Fitzgerald, M., Liu, S., Peng, C., Tang, K. H., Cao, S., Chouitar, J., Wu, J., et al. (2021) · Cancer Research · doi:10.1158/0008-5472.can-21-1526 · Cited by 57
Exon 20 YVMA insertion is associated with high incidence of brain metastasis and inferior outcome of chemotherapy in advanced non-small cell lung cancer patients with HER2 kinase domain mutations
Yang, S., Wang, Y., Zhao, C., Li, X., Liu, Q., Mao, S., Liu, Y., Yu, X., Wang, W., Tian, Q., et al. (2021) · Translational Lung Cancer Research · doi:10.21037/tlcr-20-559 · Cited by 60
National Cancer Institute Combination Therapy Platform Trial with Molecular Analysis for Therapy Choice (ComboMATCH)
Meric‐Bernstam, F., Ford, J. M., O'Dwyer, P. J., Shapiro, G. I., McShane, L. M., Freidlin, B., O'Cearbhaill, R. E., George, S., Bender, J. G., Lyman, G. H., et al. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-3334 · Cited by 59
Self-citation
Systemic treatment of advanced or recurrent biliary tract cancer
Zhang, W., Zhou, H., Wang, Y., Zhang, Z., Cao, G., Song, T., Zhang, T., & Li, Q. (2020) · BioScience Trends · doi:10.5582/bst.2020.03240 · Cited by 56
Comprehensive functional evaluation of variants of fibroblast growth factor receptor genes in cancer
Nakamura, I. T., Kohsaka, S., Ikegami, M., Ikeuchi, H., Ueno, T., Li, K., Beyett, T. S., Koyama, T., Shimizu, T., Yamamoto, N., et al. (2021) · npj Precision Oncology · doi:10.1038/s41698-021-00204-0 · Cited by 58
Precision medicine in breast cancer: From clinical trials to clinical practice
Crimini, E., Repetto, M., Aftimos, P. G., Botticelli, A., Marchetti, P., & Curigliano, G. (2021) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2021.102223 · Cited by 58
HER2-Positive Gastric Cancer and Antibody Treatment: State of the Art and Future Developments
Scheck, M. K., Hofheinz, R., & Lorenzen, S. (2024) · Cancers · doi:10.3390/cancers16071336 · Cited by 58
HER2-Selective Tyrosine Kinase Inhibitor, Zongertinib (BI 1810631), in Patients With Advanced/Metastatic Solid Tumors With HER2 Alterations: A Phase Ia Dose-Escalation Study
Heymach, J. V., Opdam, F. L., Barve, M. A., Tu, H., Wu, Y.-L. L. C., Berz, D., Schröter, L., Botilde, Y., Sadrolhefazi, B., Serra, J., et al. (2025) · Journal of Clinical Oncology · doi:10.1200/jco-24-01727 · Cited by 56
Details of human epidermal growth factor receptor 2 status in 454 cases of biliary tract cancer
Hiraoka, N., Nitta, H., Ohba, A., Yoshida, H., Morizane, C., Okusaka, T., Nara, S., Esaki, M., Kishi, Y., & Shimada, K. (2020) · Human Pathology · doi:10.1016/j.humpath.2020.08.006 · Cited by 53
Structural basis of histone H2A lysine 119 deubiquitination by Polycomb repressive deubiquitinase BAP1/ASXL1
Thomas, J. F., Valencia‐Sánchez, M. I., Tamburri, S., Gloor, S. L., Rustichelli, S., Godínez-López, V., Ioannes, P. D., Lee, R., Abini-Agbomson, S., Gretarsson, K. H., et al. (2023) · Science Advances · doi:10.1126/sciadv.adg9832 · Cited by 53
Randomized, double-blind, placebo-controlled phase II study of istiratumab (MM-141) plus nab-paclitaxel and gemcitabine versus nab-paclitaxel and gemcitabine in front-line metastatic pancreatic cancer (CARRIE)
Kundranda, M. N., Gracián, A. C., Zafar, S. F., Meiri, E., Bendell, J. C., Algül, H., Rivera, F., Ahn, E. R., Watkins, D. J., Pelzer, U., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2019.09.004 · Cited by 54
Clinical development of HER3-targeting monoclonal antibodies: Perils and progress
Jacob, W., James, I., Hasmann, M., & Weisser, M. (2018) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2018.06.011 · Cited by 52
Clinical Challenges in the Management of Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer: A Literature Review
Nagaraj, G., & Ma, C. X. (2020) · Advances in Therapy · doi:10.1007/s12325-020-01552-2 · Cited by 51
Basket trial of TRK inhibitors demonstrates efficacy in TRK fusion-positive cancers
Chen, Y., & Chi, P. (2018) · Journal of Hematology & Oncology · doi:10.1186/s13045-018-0622-4 · Cited by 51
Current and New Biomarkers for Early Detection, Prognostic Stratification, and Management of Gallbladder Cancer Patients
García, P., Lamarca, Á., Ferrer, J. D., Carrera, E., & Roa, J. C. (2020) · Cancers · doi:10.3390/cancers12123670 · Cited by 50
Management of HER2 alterations in non-small cell lung cancer – The past, present, and future
Nützinger, J., Lee, J. B., Low, J. L., Chia, P. L., Wijaya, S. T., Cho, B. C., Lim, S. M., & Soo, R. A. (2023) · Lung Cancer · doi:10.1016/j.lungcan.2023.107385 · Cited by 50
Targeting human epidermal growth factor receptor 2 (HER2) in gynecologic malignancies
Erickson, B. K., Zeybek, B., Santin, A. D., & Fader, A. N. (2019) · Current Opinion in Obstetrics & Gynecology · doi:10.1097/gco.0000000000000599 · Cited by 50
Molecular Biomarkers for Contemporary Therapies in Hormone Receptor-Positive Breast Cancer
Freelander, A., Brown, L. J., Parker, A. J., Segara, D., Portman, N., Lau, B., & Lim, E. (2021) · Genes · doi:10.3390/genes12020285 · Cited by 52
Hyperactivation of TORC1 drives resistance to the pan-HER tyrosine kinase inhibitor neratinib in HER2-mutant cancers
Sudhan, D. R., Guerrero-Zotano, A., Won, H., González Ericsson, P., Servetto, A., Huerta-Rosario, M., Ye, D., Lee, K.-M., Formisano, L., Guo, Y., et al. (2020) · Cancer Cell · doi:10.1016/j.ccell.2019.12.013 · Cited by 49
Self-citation
Next-generation sequencing-based clinical sequencing: toward precision medicine in solid tumors
Wakai, T., Prasoon, P., Hirose, Y., Shimada, Y., Ichikawa, H., & Nagahashi, M. (2018) · International Journal of Clinical Oncology · doi:10.1007/s10147-018-1375-3 · Cited by 49
Borrowing of information across patient subgroups in a basket trial based on distributional discrepancy
Zheng, H., & Wason, J. M. S. (2020) · Biostatistics · doi:10.1093/biostatistics/kxaa019 · Cited by 49
Toward a More Precise Future for Oncology
Murciano-Goroff, Y. R., Taylor, B. S., Hyman, D. M., & Schram, A. M. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.03.014 · Cited by 48
Self-citation
Can Drug Repurposing Accelerate Precision Oncology?
Schipper, L. J., Zeverijn, L. J., Garnett, M. J., & Voest, E. E. (2022) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-0612 · Cited by 52
Review of Personalized Medicine and Pharmacogenomics of Anti-Cancer Compounds and Natural Products
Zhou, Y., Peng, S., Wang, H., Cai, X., & Wang, Q. (2024) · Genes · doi:10.3390/genes15040468 · Cited by 49
Comprehensive intra-individual genomic and transcriptional heterogeneity: Evidence-based Colorectal Cancer Precision Medicine
Kyrochristos, I. D., & Roukos, D. H. (2019) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2019.101894 · Cited by 49
Dysregulation of the NRG1/ERBB pathway causes a developmental disorder with gastrointestinal dysmotility in humans
Le, T.-L., Galmiche, L., Lévy, J., Suwannarat, P., Hellebrekers, D. M. E. I., Morarach, K., Boismoreau, F., Theunissen, T. E. J., Lefebvre, M., Pelet, A., et al. (2021) · Journal of Clinical Investigation · doi:10.1172/jci145837 · Cited by 47
LobSig is a multigene predictor of outcome in invasive lobular carcinoma
Reed, A. E. M., Lal, S., Kutasovic, J. R., Wockner, L. F., Robertson, A. J., Luca, X. M. D., Croft, P. K., Dalley, A. J., Coorey, C. P., Kuo, L. Y., et al. (2019) · npj Breast Cancer · doi:10.1038/s41523-019-0113-y · Cited by 47
Afatinib in patients with advanced non-small cell lung cancer harboring HER2 mutations, previously treated with chemotherapy: A phase II trial
Fan, Y., Chen, J., Zhou, C., Wang, H., Shu, Y., Zhang, J., Huang, D., Huang, D. C.-L., & Zhou, C. (2020) · Lung Cancer · doi:10.1016/j.lungcan.2020.07.017 · Cited by 46
Prevalence of HER2 overexpression and amplification in cervical cancer: A systematic review and meta-analysis
Itkin, B., Garcia, A., Straminsky, S., Adelchanow, E. D., Pereyra, M. G., Haab, G. A., & Bardach, A. (2021) · PLoS ONE · doi:10.1371/journal.pone.0257976 · Cited by 46
Association between histone lysine methyltransferase KMT2C mutation and clinicopathological factors in breast cancer
Chen, X., Zhang, G., Chen, B., Wang, Y., Guo, L., Cao, L., Ren, C., Wen, L., & Liao, N. (2019) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2019.108997 · Cited by 46
The genomic landscape of metastatic histologic special types of invasive breast cancer
Pareja, F. G., Ferrando, L., Lee, S., de Beça, F. F., Selenica, P., Brown, D. N., Farmanbar, A., Paula, A. D. C., Vahdatinia, M., Zhang, H., et al. (2020) · npj Breast Cancer · doi:10.1038/s41523-020-00195-4 · Cited by 47
Selective advantage of epigenetically disrupted cancer cells via phenotypic inertia
Loukas, I., Simeoni, F., Milan, M., Inglese, P., Patel, H., Goldstone, R. J., East, P., Strohbuecker, S., Mitter, R., Talsania, B., et al. (2022) · Cancer Cell · doi:10.1016/j.ccell.2022.10.002 · Cited by 46
Genomic Landscape and Clinical Utility in Korean Advanced Pan-Cancer Patients from Prospective Clinical Sequencing: K-MASTER Program
Park, K. H., Choi, J. Y., Lim, A.-R., Kim, J. W., Choi, Y. J., Lee, S. H., Sung, J. S., Chung, H.-J., Jang, B., Yoon, D., et al. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-1064 · Cited by 45
Randomized clinical trials and personalized medicine: A commentary on deaton and cartwright
Schork, N. J. (2018) · Social Science & Medicine · doi:10.1016/j.socscimed.2018.04.033 · Cited by 45
Conformational Landscapes of HER2 Exon 20 Insertions Explain Their Sensitivity to Kinase Inhibitors in Lung Adenocarcinoma
Zhao, S., Fang, W., Pan, H., Yang, Y., Liang, Y., Yang, L., Dong, X., Zhan, J., Wang, K., & Zhang, L. (2020) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2020.01.020 · Cited by 45
Use of Ex Vivo Patient-Derived Tumor Organotypic Spheroids to Identify Combination Therapies for HER2 Mutant Non–Small Cell Lung Cancer
Ivanova, E. V., Kuraguchi, M., Xu, M., Portell, A. J., Taus, L. J., Diala, I., Lalani, A. S., Choi, J., Chambers, E. S., Li, S., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-1844 · Cited by 45
Self-citation
Biliary Tract Cancers: Molecular Heterogeneity and New Treatment Options
Personeni, N., Lleò, A., Pressiani, T., Colapietro, F., Openshaw, M. R., Stavraka, C., Pouptsis, A., Pinato, D. J., & Rimassa, L. (2020) · Cancers · doi:10.3390/cancers12113370 · Cited by 45
HER2-targeted therapy: an emerging strategy in advanced colorectal cancer
Salvia, A. L., López-Gómez, V., & García‐Carbonero, R. (2018) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2019.1555583 · Cited by 44
Agnostic-Histology Approval of New Drugs in Oncology: Are We Already There?
Hierro, C., Matos, I. G., Martín-Liberal, J., de Olza, M. O., & Garralda, E. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-3694 · Cited by 44
Targetable ERBB2 mutations identified in neurofibroma/schwannoma hybrid nerve sheath tumors
Ronellenfitsch, M. W., Harter, P. N., Kirchner, M., Heining, C., Hutter, B., Gieldon, L., Schittenhelm, J., Schuhmann, M. U., Tatagiba, M. S., Marquardt, G., et al. (2020) · Journal of Clinical Investigation · doi:10.1172/jci130787 · Cited by 44

Authors: Hyman, D. M., Piha-Paul, S. A., Won, H., Rodon, J., Saura, C., Shapiro, G. I., Juric, D., Quinn, D. I., Moreno, V., Doger, B., Mayer, I. A., Boni, V., Calvo, E., Loi, S., Lockhart, A. C., Erinjeri, J. P., Scaltriti, M., Ulaner, G. A., Patel, J., Tang, J., Beer, H., Selcuklu, S. D., Hanrahan, A. J., Bouvier, N., Melcer, M., Murali, R., Schram, A. M., Smyth, L. M., Jhaveri, K., Li, B. T., Drilon, A., Harding, J. J., Iyer, G., Taylor, B. S., Berger, M. F., Cutler Jr, R. E., Xu, F., Butturini, A., Eli, L. D., Mann, G., Farrell, C., Lalani, A. S., Bryce, R. P., Arteaga, C. L., Meric-Bernstam, F., Baselga, J., & Solit, D. B.
Affiliations: Memorial Sloan Kettering Cancer Center (US)
The University of Texas MD Anderson Cancer Center (US)
Vall d'Hebron Hospital Universitari (ES)
Dana-Farber Cancer Institute (US)
USC Norris Comprehensive Cancer Center (US)
Vanderbilt University (US)
Peter MacCallum Cancer Centre (AU)
Washington University in St. Louis (US)
Puma Biotechnology (United States) (US)
Corresponding author: Hyman, David M.
ORCID: Hyman, David M.
Piha-Paul, Sarina A.
Won, Helen
Rodon, Jordi
Saura, Cristina
Shapiro, Geoffrey I.
Juric, Dejan
Quinn, David I.
Mayer, Ingrid A.
Boni, Valentina
Calvo, Emiliano
Loi, Sherene
Lockhart, Albert C.
Erinjeri, Joseph P.
Scaltriti, Maurizio
Ulaner, Gary A.
Patel, Juber
Bouvier, Nancy
Murali, Rajmohan
Schram, Alison M.
Smyth, Lillian M.
Jhaveri, Komal
Li, Bob T.
Drilon, Alexander
Harding, James J.
Iyer, Gopa
Taylor, Barry S.
Berger, Michael F.
Xu, Feng
Eli, Lisa D.
Lalani, Alshad S.
Bryce, Richard P.
Arteaga, Carlos L.
Solit, David B.
Venue: Nature
Publisher: Springer Science and Business Media LLC
Published: 2018-01-31
Volume: 554
Issue: 7691
Pages: 189-194
ISSN: 0028-0836 (ISSN-L)
1476-4687
DOI: 10.1038/nature25475
PMC: PMC5808581
OpenAlex: W2785610956
Cited by: 780
References: 54
Citations by year: 2026: 40 · 2025: 64 · 2024: 89 · 2023: 99 · 2022: 113 · 2021: 103 · 2020: 113 · 2019: 86 · 2018: 69
FWCI: 34.53
Type: journal article
Language: en
Update notices: correction (2019-02-12)
Open access: green
www.ncbi.nlm.nih.gov
Licence: www.springer.com/tdm (tdm)
Locations: Nature (publishedVersion)
PubMed (publishedVersion)
Europe PMC (PubMed Central) (acceptedVersion)
PubMed Central (acceptedVersion)
RePEc: Research Papers in Economics (submittedVersion)
Minerva Access (University of Melbourne) (submittedVersion)
Funders: Puma Biotechnology
National Institutes of Health (UL1TR000371)
National Cancer Institute (R01CA204749, U01CA180964, R01CA080195, P50CA098131, P30CA008748, P30CA016672, T32CA009207, R25CA020449, P30CA014089)
National Center for Advancing Translational Sciences
Topics: Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
Keywords: HER2 mutation, ERBB2, HER3, neratinib, basket trials, breast cancer, biliary tract cancer, cervical cancer, targeted therapy
MeSH terms: Adult, Aged, Aged, 80 and over, Alleles, Antineoplastic Agents, Female, Humans, Male, Middle Aged, Mutation, Neoplasms, Quinolines, Cohort Studies, Treatment Outcome, Erb-b2 Receptor Tyrosine Kinases, Mutation, Missense, Receptor, ErbB-3, Protein Kinase Inhibitors, Molecular Targeted Therapy

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

HER kinase inhibition in patients with HER2- and HER3-mutant cancers

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks